Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 6/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672155 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPK10SMN1; SMN2MIFHDAC6 | |
| SCHEMBL5662697 | 0.86 | ALDH1A1 (0.48) | ALDH1A1MAPK10SMN1; SMN2MIFHDAC6 | |
| SCHEMBL3986303 | 0.86 | ALDH1A1 (0.45) | ALDH1A1MAPK10SMN1; SMN2MIFHDAC6 | |
| SCHEMBL21065803 | 0.82 | CLK4 (0.42) | — | |
| SCHEMBL2920841 | 0.81 | — | — | |
| SCHEMBL7367279 | 0.81 | MIF (0.71) | ALDH1A1MAPK10SMN1; SMN2MIFHDAC6 | |
| SCHEMBL7214876 | 0.81 | MIF (0.71) | ALDH1A1MAPK10SMN1; SMN2MIFHDAC6 | |
| SCHEMBL6995730 | 0.81 | MIF (0.71) | ALDH1A1MAPK10SMN1; SMN2MIFHDAC6 | |
| SCHEMBL5637433 | 0.81 | MAPT (0.45) | ALDH1A1MAPK10SMN1; SMN2MIFHDAC6 | |
| SCHEMBL22839964 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPK10SMN1; SMN2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660333-B2 | Substituted 2-heterocyclylimidazolylcarboxamides as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20190166837-A1 | SUBSTITUTED 2-HETEROCYCLYLIMIDAZOLYLCARBOXAMIDES AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-06-06 | — | — | US | disclosed |
| US-7238690-B2 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-RE39680-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7183282-B2 | Substituted heterocycle fused γ-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | ALDH1A1 704/4885MAPK10 1845/4885SMN1; SMN2 1565/4885 |
| US-20190166837-A1 | SUBSTITUTED 2-HETEROCYCLYLIMIDAZOLYLCARBOXAMIDES AS PESTICIDES | DDT, PTMS, TSNAX | ALDH1A1 3634/4885MAPK10 4781/4885SMN1; SMN2 2938/4885 |
| US-10660333-B2 | Substituted 2-heterocyclylimidazolylcarboxamides as pesticides | DDT, PTMS, TSNAX | ALDH1A1 3634/4885MAPK10 4781/4885SMN1; SMN2 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.